KN8.F KRKA D.D. A NA
- Market cap
- EUR 7.43B
- P/E
- 17.8x
- P/B
- 2.89x
- ROE
- 19.9%
- Dividend yield
- 3.39%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is KN8.F undervalued?
Graham numberKN8.F trades 51.4% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
KRKA D.D. A NA fundamental analysis
No fundamental analysis for KRKA D.D. A NA yet.
KRKA D.D. A NA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About KRKA D.D. A NA
Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. The company offers prescription pharmaceuticals for cardiovascular, central nervous system, gastrointestinal tract, pain, diabetes, and other therapeutic areas. It also provides non-prescription products for cough,…
Full company profileKRKA D.D. A NA financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
KRKA D.D. A NA annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 1.57B | 1.72B | 1.81B | 1.91B | 2.04B | 2.24B |
| Gross Profit | 891M | 974M | 1.03B | 1.09B | 1.18B | 1.36B |
| Operating Income | 355M | 381M | 394M | 423M | 466M | 619M |
| EBITDA | - | 542M | 472M | 512M | 596M | 737M |
| Net Income | 309M | 363M | 314M | 357M | 403M | 521M |
| EPS | 9.94 | 12 | 10 | 12 | 13 | 17 |
| Balance Sheet | ||||||
| Total Assets | 2.54B | 2.69B | 2.76B | 2.85B | 3.04B | 3.33B |
| Total Liabilities | 618M | 549M | 583M | 611M | 666M | 700M |
| Shareholders' Equity | 1.91B | 2.12B | 2.16B | 2.22B | 2.36B | 2.61B |
| Cash & Short-term Investments | 160M | 519M | 174M | 345M | 348M | 388M |
| Cash Flow | ||||||
| Operating Cash Flow | 386M | 468M | 227M | 361M | 529M | 451M |
| Capital Expenditure | 72.1M | 94.7M | 139M | 115M | 98.3M | 115M |
| Free Cash Flow | 314M | 373M | 88.0M | 246M | 430M | 336M |
| Ratios | ||||||
| ROE | 16.2% | 17.1% | 14.5% | 16.1% | 17.1% | 19.9% |
| ROA | 12.2% | 13.5% | 11.4% | 12.5% | 13.3% | 15.6% |
| Net Profit Margin | 19.7% | 21.2% | 17.4% | 18.7% | 19.8% | 23.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
KRKA D.D. A NA dividends
- Dividend yield
- 3.39%
- Forward dividend
- 9.10 EUR
- Payout ratio
- 62.5%
- Ex-dividend date
- Jul 21, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 252M | 8.30 | 62.5% |
| 2024 | EUR 231M | 7.52 | 64.7% |
| 2023 | EUR 204M | 6.62 | 65.1% |
| 2022 | EUR 175M | 5.65 | 48.2% |
| 2021 | EUR 156M | 5.01 | 50.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns KRKA D.D. A NA
- Insiders 16.33%
- Institutions 12.72%
- Public & others 70.95%
- Shares outstanding 30.3M
- Free float 21.0M
KRKA D.D. A NA company profile
- Company name
- KRKA D.D. A NA
- Ticker
- KN8.F
- ISIN
- SI0031102120
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 13,300
- Fiscal year end
- December
- Address
- ?marje?ka cesta 6, Novo Mesto, Slovenia, 8501
- Phone
- 386 7 331 2111
- Website
- krka.biz
About KRKA D.D. A NA
Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. The company offers prescription pharmaceuticals for cardiovascular, central nervous system, gastrointestinal tract, pain, diabetes, and other therapeutic areas. It also provides non-prescription products for cough, cold, cerebral, peripheral circulation, gastrointestinal tract, metabolism, and other therapeutic areas, as well as analgesics, vitamins, minerals, and vasoprotectives. In addition, the company offers animal health products, including antiparasitics, antimicrobials, and other products. Further, it provides health resort and tourist services. The company was founded in 1954 and is based in Novo Mesto, Slovenia.
KRKA D.D. A NA management
10- Dr. Jo?e ColaricPresident of Management Board & CEO · born 1955
- Dr. Mateja Vrecer Ph.D.Director of Quality Management & Employee Representative Deputy President of the Supervisory Board · born 1966
- Dr. Ales Rotar Ph.D.Member of the Management Board and Director of Pharmaceutical R&D & Production · born 1960
- Mr. David BratozMember of the Management Board · born 1976
- Dr. Vinko Zupancic Ph.D.Director of API R&D, Production & Supply Chain and Member of the Management Board · born 1971
- Ms. Milena KastelicMember of the Mgt. Board, Worker Director & Deputy Dir. of Pharmaceutical Production · born 1968
- Magistrate Toma? Sever MScDty Director of Sales, Director of Region Central Europe & Ind Employee Rep Member of Super Board · born 1967
- Dr. Mari BozicEmployee Representative Supervisory Board Member & Assistant Head of Pharmaceutical Development · born 1964
- Uros OzboltDirector of Finance
- Matej BaseljTechnical Director